Axitinib versus sorafenib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)

被引：28

作者：

Hutson, Thomas E.

Gallardo, Jorge

Lesovoy, Vladmir

Al-Shukri, Salman

Stus, Viktor

Bair, A. H.

Rosbrook, Brad

Bycott, Paul W.

Tarazi, Jamal Christo

Kim, Sinil

Vogelzang, Nicholas J.

机构：

[1] Baylor Charles Sammons Canc Ctr, Dallas, TX USA

[2] US Oncol Res, Dallas, TX USA

[3] Inst Terapias Oncol, Santiago, Chile

[4] Kharkiv Reg Clin Ctr Urol & Nephrol, Kharkov, Ukraine

[5] St Petersburg State Med Univ, St Petersburg, Russia

[6] Dnipropetrovsk Reg Clin Hosp, Dnepropetrovsk, Ukraine

[7] Pfizer Oncol, San Diego, CA USA

[8] Comprehens Canc Ctr Nevada, Las Vegas, NV USA

[9] US Oncol Res, Las Vegas, NV USA

来源：

关键词：

D O I：

10.1200/jco.2013.31.6_suppl.lba348

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

LBA348

引用

页数：1